How to Help Your Patients Find Caverject in Stock: A Provider's Guide

Following Pfizer's discontinuation of the Caverject brand in July 2025, your patients may be calling the office confused, frustrated, or unable to fill their prescriptions. This guide provides concrete, actionable steps your practice can take to minimize disruption and help patients maintain their erectile dysfunction treatment.

Step 1: Proactively Identify Affected Patients

Run a query of your patient management system to identify all patients currently prescribed Caverject, Caverject Impulse, or alprostadil injection. This allows your staff to proactively reach out rather than waiting for patients to call in with a crisis. A proactive letter or patient portal message explaining the brand transition — and what to expect — reduces call volume and patient anxiety.

Step 2: Establish Relationships with Specialty and Compounding Pharmacies

The most important logistical step your practice can take is identifying one or more reliable pharmacy partners for injectable ED medications. Options include:

Specialty pharmacies: Pharmacies specializing in urology, oncology, or compounded medications are significantly more likely to stock generic alprostadil injection than general retail chains.

Compounding pharmacies: For patients who may benefit from Trimix or for whom generic alprostadil remains hard to find, a trusted compounding pharmacy is invaluable. Verify PCAB accreditation or state board credentials for compounders you refer to.

Mail-order specialty pharmacies: Some insurance-contracted mail-order pharmacies reliably stock injectable ED medications at lower copays. Know which ones are in your patients' networks.

Step 3: Update Prescription Language

Prescriptions written specifically for 'Caverject' or 'Caverject Impulse' may create obstacles at the pharmacy counter since the brand is discontinued. Update your default prescribing templates to use the generic name 'alprostadil injection' with the appropriate dose and formulation. For patients who prefer Edex (Endo's still-available brand), rewrite accordingly.

Also verify that your e-prescribing system has been updated to reflect the brand discontinuation so that Caverject doesn't appear as an available option, which could generate confusing prescriptions.

Step 4: Evaluate Which Patients Are Good Candidates for Trimix

The brand transition is a clinically appropriate moment to reassess whether Trimix (alprostadil + papaverine + phentolamine) is a better option for certain patients. Good candidates for Trimix transition include:

Patients who reported significant penile pain with Caverject

Patients who required high doses (>20 mcg alprostadil) for adequate response

Patients for whom cost is a concern (Trimix is often less expensive per dose)

Remember that Trimix requires in-office dose titration. Schedule these patients for a brief procedure visit rather than attempting a phone-based transition.

Step 5: Verify Insurance Prior Authorization Status

Most major insurers (Cigna, BCBS, Health Net) require prior authorization for alprostadil products. Existing authorizations may be for the brand name 'Caverject' — a new PA request may be needed when switching to generic alprostadil or Edex. Check with each insurer and have your staff submit updated PA documentation proactively before patients run out of medication.

Step 6: Share medfinder with Patients Who Are Struggling

For patients who have a valid prescription but cannot find a local pharmacy with their medication in stock, medfinder for providers is a resource you can recommend. medfinder contacts local pharmacies on the patient's behalf to determine which ones can fill their specific prescription. Patients simply provide their medication, dose, and zip code — medfinder calls the pharmacies and texts them results.

This reduces both patient frustration and the volume of 'I can't find my medication' calls your staff receives.

Clinical Safety Reminders for Injectable ED Therapy

Dose titration: always performed in office for new formulations or brand changes

Frequency: no more than 3 injections per week; minimum 24 hours between doses

Priapism protocol: patients must know to seek emergency care for any erection lasting >4 hours

Fibrosis monitoring: periodic penile examination; discontinue if fibrosis or angulation develops

Anticoagulant interaction: compress injection site for 5 minutes in patients on warfarin or heparin

See also: Caverject shortage: What providers and prescribers need to know in 2026.